Table 1.

Summary of current NASH medications recommended by international guidelines

Drugs	Mechanism	Population	Guidelines (level of recommendation)
Vitamin E	Anti-oxidant	Non-diabetic patients with biopsy-proven NASH	AASLD 2018*
			EASL 2016 (B2)
			KASL 2021 (B1)
			AACE 2022 (Grade B, high strength of evidence)
Pioglitazone	PPAR-γ agonist	Diabetic patients with biopsy- proven NASH	AASLD 2018*
			EASL 2016 (B2)
			KASL 2021 (B1)
			AACE 2022 (Grade A, high strength of evidence)

NASH, nonalcoholic steatohepatitis; PPAR, peroxisome proliferator-activated receptor; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; KASL, Korean Association for the Study of the Liver; AACE, American Association of Clinical Endocrinology.

^*The level and length of recommendations were not presented in the AASLD guidance 2018.